Purisys has agreed to supply Cannabics Pharmaceuticals, a global developer of cancer-related cannabinoid-based medicine, with GMP-grade APIs required for the manufacturing of its colorectal cancer treatment drug candidate.

According to Josh Hoerner, Purisys General Manager, the company will provide Cannabics with pharmaceutical-grade ultra-pure cannabinoid APIs for their drug candidate RCC-33 ― which is billed as the world’s first cannabinoid-based antitumour drug candidate for the treatment of colorectal cancer ― using state-of-the-art manufacturing technology.

In addition, the synthetically derived API manufacturer will also support Cannabics throughout an investigational new drug (IND) filing process, including providing all necessary regulatory and chemistry manufacturing and controls- (CMC) related support for its planned approach of the FDA.

APIs supplied under the agreement will be used by Cannabics ― a US public company with R&D capabilities based in Israel ― in Phase I/II (a) clinical studies that it is planning to launch in 2022.